Julie Hambleton
Director/Board Member at IGM BIOSCIENCES, INC.
Net worth: 260 435 $ as of 30/03/2024
Profile
Julie Hambleton is an Independent Director at IGM Biosciences, Erasca, Springworks Therapeutics, Onc.ai, and Gennao Bio.
She was the President, Chief Executive Officer & Director at Arch Oncology, Inc. from 2020 to 2021.
She was the Medical Director-Global Clinical Development at Genentech, Inc. from 2003 to 2010.
She was the Chief Medical Officer & Executive Vice President at Five Prime Therapeutics, Inc. from 2015 to 2016.
She was an Associate Professor at The University of California, San Francisco from 1993 to 2003.
She was the Vice President-Clinical Development at Clovis Oncology, Inc. from 2010 to 2012.
She was the Vice President & Head-US Medical at Bristol Myers Squibb Co. from 2016 to 2017.
She was the Director at Accent Therapeutics, Inc. from 2020 to 2021.
She was the Chief Medical Officer, SVP & Head-Development at IDEAYA Biosciences, Inc. from 2018 to 2020.
She received her undergraduate degree from Duke University and her doctorate from Case Western Reserve University School of Medicine.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 24/03/2024 | 4,648 ( 0.01% ) | 228 775 $ | 30/03/2024 | |
IGM BIOSCIENCES, INC.
0.01% | 11/03/2024 | 2,000 ( 0.01% ) | 19 300 $ | 30/03/2024 |
ERASCA, INC.
0.00% | 14/04/2023 | 6,000 ( 0.00% ) | 12 360 $ | 30/03/2024 |
Julie Hambleton active positions
| Companies | Position | Start |
|---|---|---|
| IGM BIOSCIENCES, INC. | Director/Board Member | 14/08/2018 |
| SPRINGWORKS THERAPEUTICS, INC. | Director/Board Member | 19/05/2020 |
| ERASCA, INC. | Director/Board Member | 28/03/2021 |
Gennao Bio, Inc.
 Gennao Bio, Inc. Pharmaceuticals: MajorHealth Technology Gennao Bio, Inc. is a privately-held genetic medicines company that is developing first-in-class, non-viral, targeted nucleic acid therapeutics utilizing its proprietary gene monoclonal antibody (gmab) platform technology. The company is based in Pennington, NJ. The company's gmab technology uses a novel, cell-penetrating antibody to non-covalently bind to, and deliver therapeutic levels of a wide variety of nucleic acid payloads, to select cells. Gennao Bio is initially focusing on addressing significant unmet needs in oncology and rare monogenic skeletal muscle diseases. The company's non-viral delivery platform offers significant advantages over traditional gene delivery systems as it can deliver multiple types of nucleic acids, allows for repeat dosing and dose optimization, and can be easily and affordably manufactured. The company was founded in 2020 by Bruce Turner, Elias Quijano, Peter M. Glazer, Stephen P. Squinto. Christopher M. Duke has been the CEO of the company since 2021. | Director/Board Member | 12/07/2021 |
Onc.ai, Inc.
 Onc.ai, Inc. Packaged SoftwareTechnology Services Onc.ai, Inc. is a digital health company that is privately held and is developing a precision oncology care management platform. The company is based in San Carlos, CA. The company aims to transform clinical decision making and is backed by premier investment firms such as the Blue Venture Fund, MassMutual Alternative Investments, and Accomplice, among others. The company is building a pipeline of physician-centered products to fulfill the potential of precision oncology. The company was founded by Akshay Nanduri, who has been the CEO since incorporation. | Director/Board Member | - |
Former positions of Julie Hambleton
| Companies | Position | End |
|---|---|---|
Arch Oncology, Inc.
 Arch Oncology, Inc. Miscellaneous Commercial ServicesCommercial Services Arch Oncology, Inc. develops drugs for life-threatening disorders. Its products include anti-CD47 monoclonal antibody, CD47 antisense oligonucleotide, and a small molecule CD47 inhibitor. The company was founded by William A. Frazier and Jeffrey S. Isenberg in 2006 and is headquartered in Brisbane, CA. | Chief Executive Officer | 31/03/2021 |
Accent Therapeutics, Inc.
 Accent Therapeutics, Inc. BiotechnologyHealth Technology Accent Therapeutics, Inc. operates as a biopharmaceutical company which develops treatments for cancer patients. The company was founded by Howard Y. Chang, Chuan He and Robert A. Copeland in September 2017 and is headquartered in Lexington, MA. | Director/Board Member | 28/02/2021 |
| IDEAYA BIOSCIENCES, INC. | Chief Tech/Sci/R&D Officer | 29/04/2020 |
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | 31/08/2017 |
| ░░░░ ░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░ ░░░░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ |
Training of Julie Hambleton
| Duke University | Undergraduate Degree |
| Case Western Reserve University School of Medicine | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 5 |
|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| IDEAYA BIOSCIENCES, INC. | Health Technology |
| IGM BIOSCIENCES, INC. | Health Technology |
| ERASCA, INC. | Health Technology |
| SPRINGWORKS THERAPEUTICS, INC. | Health Technology |
| Private companies | 7 |
|---|---|
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Health Technology |
Five Prime Therapeutics, Inc.
 Five Prime Therapeutics, Inc. BiotechnologyHealth Technology Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of novel protein therapeutics. Its product candidates includes, Cabiralizumab (FPA008), Bemarituzumab (FPA144), and FPA150. The FPA008 is an antibody that inhibits colony stimulating factor-1, or CSF1, receptor, or CSF1R, that are developing in rheumatoid arthritis and plan to clinically develop in pigmented villonodular synovitis, or PVNS, and in combination with nivolumab in multiple cancers. The FPA144 is an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, that are developing to treat patients with gastric cancer. The FPA150 is a CD8 T cell checkpoint which targets B7-H4 that is developing as a monotherapy in multiple cancers. The company was founded by Lewis T. Williams in December 2001 and is headquartered in South San Francisco, C. | Health Technology |
Clovis Oncology, Inc.
 Clovis Oncology, Inc. Pharmaceuticals: MajorHealth Technology Clovis Oncology, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of innovative anti-cancer agents in the United States, Europe, and additional international markets. Its U.S. marketed product, Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase (PARP), is approved for use in the maintenance treatment and treatment of eligible adult patients with recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer, and also for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC), which have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. In Europe, Rubraca is approved for use in recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer. The company was founded by Andrew R. Allen, Gillian C. Ivers-Read, Patrick J. Mahaffy, and Erle T. Mast on April 20, 2009 and is headquartered in Boulder, CO. | Health Technology |
Arch Oncology, Inc.
Arch Oncology, Inc. Miscellaneous Commercial ServicesCommercial Services Arch Oncology, Inc. develops drugs for life-threatening disorders. Its products include anti-CD47 monoclonal antibody, CD47 antisense oligonucleotide, and a small molecule CD47 inhibitor. The company was founded by William A. Frazier and Jeffrey S. Isenberg in 2006 and is headquartered in Brisbane, CA. | Commercial Services |
Accent Therapeutics, Inc.
Accent Therapeutics, Inc. BiotechnologyHealth Technology Accent Therapeutics, Inc. operates as a biopharmaceutical company which develops treatments for cancer patients. The company was founded by Howard Y. Chang, Chuan He and Robert A. Copeland in September 2017 and is headquartered in Lexington, MA. | Health Technology |
Onc.ai, Inc.
Onc.ai, Inc. Packaged SoftwareTechnology Services Onc.ai, Inc. is a digital health company that is privately held and is developing a precision oncology care management platform. The company is based in San Carlos, CA. The company aims to transform clinical decision making and is backed by premier investment firms such as the Blue Venture Fund, MassMutual Alternative Investments, and Accomplice, among others. The company is building a pipeline of physician-centered products to fulfill the potential of precision oncology. The company was founded by Akshay Nanduri, who has been the CEO since incorporation. | Technology Services |
Gennao Bio, Inc.
Gennao Bio, Inc. Pharmaceuticals: MajorHealth Technology Gennao Bio, Inc. is a privately-held genetic medicines company that is developing first-in-class, non-viral, targeted nucleic acid therapeutics utilizing its proprietary gene monoclonal antibody (gmab) platform technology. The company is based in Pennington, NJ. The company's gmab technology uses a novel, cell-penetrating antibody to non-covalently bind to, and deliver therapeutic levels of a wide variety of nucleic acid payloads, to select cells. Gennao Bio is initially focusing on addressing significant unmet needs in oncology and rare monogenic skeletal muscle diseases. The company's non-viral delivery platform offers significant advantages over traditional gene delivery systems as it can deliver multiple types of nucleic acids, allows for repeat dosing and dose optimization, and can be easily and affordably manufactured. The company was founded in 2020 by Bruce Turner, Elias Quijano, Peter M. Glazer, Stephen P. Squinto. Christopher M. Duke has been the CEO of the company since 2021. | Health Technology |
- Stock Market
- Insiders
- Julie Hambleton
